Market Performance - A-shares continued strong performance with the Shanghai Composite Index reaching a high of 3879.05 points, closing at 3862.65 points, up 0.12% [2] - The Shenzhen Component Index and the ChiNext Index rose by 0.11% and 0.55% respectively [2] Gold Market - The precious metals sector saw significant gains, with international gold prices reaching new highs; COMEX gold peaked at $3552 per ounce, marking a year-to-date increase of approximately 35% [6][8] - London spot gold prices also rose, reaching $3486.16 per ounce, just shy of the historical high of $3500 from April [8] - A-share gold stocks surged, with Western Gold hitting the daily limit, and several other stocks like Xiaocheng Technology and Hunan Gold also showing strong gains [8][9] AI Computing Sector - The AI computing sector exhibited mixed performance; stocks like Xuanji Information and Liyang Chip hit the daily limit, while Cambrian experienced a decline of nearly 3% [10][11] - Cambrian's stock fluctuated significantly, dropping over 8% before stabilizing to a decrease of 2.98% by midday [11][12] - Reports indicated that rumors about Alibaba purchasing 150,000 Cambrian GPUs were unfounded [12] Alibaba's Market Activity - Alibaba's stock surged over 16% in Hong Kong, with a market capitalization increase of approximately HKD 400 billion, reaching a total market value of HKD 2.59 trillion [15][16] - The company reported a revenue of RMB 247.65 billion for Q1 of the 2026 fiscal year, with a net profit of RMB 43.12 billion, reflecting a 76% year-on-year increase [15][17] - Alibaba plans to invest RMB 380 billion over three years in AI infrastructure, which is expected to drive demand for computing power [17] Innovative Drug Sector - The innovative drug sector saw significant activity, with MicroPort Medical rising over 14% and achieving a year-to-date increase of over 109% [18] - MicroPort's new stent technology demonstrated clinical advantages, reducing treatment duration and complications [18] - The approval of 43 innovative drugs in the first half of the year indicates a growing focus on drug development in China, with the biotech index showing a year-to-date increase of over 101% [18]